We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ALXO ALX Oncology Holdings Inc

0.22 (1.79%)
Last Updated: 12:52:30
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
ALX Oncology Holdings Inc ALXO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.22 1.79% 12.48 12:52:30
Open Price Low Price High Price Close Price Previous Close
12.25 11.441 12.65 12.26
more quote information »

Recent News

Date Time Source Heading
11/13/202315:05GLOBEALX Oncology Reports Third Quarter 2023 Financial Results..
11/13/202315:03EDGAR2Form 8-K - Current report
11/01/202315:05GLOBEALX Oncology Announces November Investor Conference..
10/10/202315:05GLOBEALX Oncology Announces Closing of Public Offering, Including..
10/06/202305:06EDGAR2Form 8-K - Current report
10/06/202305:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/05/202307:00GLOBEALX Oncology Announces Pricing of Public Offering
10/04/202316:21EDGAR2Form 8-K - Current report
10/04/202316:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/04/202315:10GLOBEALX Oncology Announces Proposed Public Offering
10/04/202307:00EDGAR2Form 8-K - Current report
10/03/202309:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
10/03/202305:00GLOBEALX Oncology Reports Positive Interim Phase 2 ASPEN-06..
10/02/202315:05GLOBEALX Oncology to Host Investor Call and Webcast on October 3,..
9/20/202307:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
9/10/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
9/08/202315:25EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
9/06/202315:05EDGAR2Form 8-K - Current report
9/06/202307:00GLOBEALX Oncology Realigns Executive Leadership Team
9/01/202315:11EDGAR2Form S-3 - Registration statement under Securities Act of..
8/31/202306:00GLOBEALX Oncology Announces September Investor Conference..
8/25/202315:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
8/10/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/202315:05EDGAR2Form 8-K - Current report
8/10/202315:01GLOBEALX Oncology Reports Second Quarter 2023 Financial Results..
7/27/202315:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/27/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/27/202315:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/07/202315:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/05/202316:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/05/202316:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/05/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
6/26/202306:00GLOBEALX Oncology Receives Orphan Drug Designation from the..
5/11/202315:01GLOBEALX Oncology Reports First Quarter 2023 Financial Results..
5/09/202306:00GLOBEALX Oncology Announces First Patient Dosed in Phase 2..
4/25/202306:00GLOBEALX Oncology Announces Clinical Trial Collaboration with..
3/14/202307:00PRNUSALX Oncology and Quantum Leap Healthcare CollaborativeTM..
3/13/202306:00GLOBEALX Oncology and Quantum Leap Healthcare Collaborativeā„¢..
3/09/202315:01GLOBEALX Oncology Reports Fourth Quarter and Full Year 2022..
2/16/202306:00GLOBEALX Oncology Announces First Patient Dosed in ASPEN-07, a..
1/05/202306:00GLOBEALX Oncology Provides Corporate Update and Highlights Key..
1/03/202306:00GLOBEALX Oncology to Present at the 41st Annual J.P. Morgan..
12/12/202209:00GLOBEALX Oncology Announces Initial Data from ASPEN-05 Study of..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |